The study analyzed 5,173 participants 45 years old with BMI 27 kg/m from the Mass General Brigham CCTA Registry, excluding those with prior myocardial infarction, revascularization, stroke, or diabetes
Under no circumstances should you shake the vial
Cardiovascular mortality Compared with placebo, tirzepatide and the GLP-1RA class significantly reduced the risk of CV mortality (HR 0.77, 95% CI 0.660.90 and HR 0.87, 95% CI 0.810.92, respectively).- Heterogeneity across studies was low (Q = 11.76, p = 0.227
La liposculpture VASER Paris vous offre la possibilit de redessiner votre silhouette avec prcision
In the Phase 3 REDEFINE 1 trial, cagrilintide monotherapy achieved 11.8% average weight loss over 68 weekscomparable to semaglutide but with a notably lower incidence of nausea and vomiting, making it a potential option for patients who dont tolerate GLP-1 medications well
Gisondi P, Fantin F, Del Giglio M, Valbusa F, Marino F, Zamboni M, Girolomoni G
)
